SAN DIEGO, Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients, announces the
award of Japanese Patent No. 6734887, entitled METHODS FOR
DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides
intellectual property protection for the Primer-Switch technology,
which is useful for the detection of rare mutations, including
cancer biomarkers, found in tissue, blood and cerebrospinal fluid
using circulating tumor DNA (ctDNA) analysis through real-time PCR
and associated analysis methods, including next-generation
sequencing (NGS).
This is the third issued patent for the Primer-Switch technology
as Biocept pursues worldwide patent protection for this technology.
The Primer-Switch technology provides a method for specifically
enriching patient specimens for oncogene mutations of interest.
Additionally, the Primer-Switch technology can be used to
enhance the performance and specificity of the PCR method, which is
the most widely used amplification approach in research and
molecular diagnostics, including clinical applications. Biocept
holds certain rights to the Primer-Switch technology within the
field of clinical oncology.
"The Primer-Switch detection and amplification platform has the
potential to find rare mutations in PCR reactions, which is highly
useful when there is a need to detect rare genetic events or when
more precise PCR amplification reactions are desired or required,"
Michael Nall,
Biocept's President and CEO. "This technology builds upon
the ability to detect rare genetic events which is the key target
in our Target Selector™ ctDNA assays. We continue to expand
our intellectual property portfolio to protect this method that
differentiates Biocept from others in the liquid biopsy space."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to support
efforts to fight the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, and the utility and
effectiveness of our intellectual property protections, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at http://www.sec.gov/.
Investor Contact:
LHA Investor Relations
Jody
Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-announces-the-award-of-japanese-patent-for-primer-switch-mutation-detection-and-amplification-improvement-platform-used-to-detect-rare-cell-mutations-in-tissue-blood-and-cerebrospinal-fluid-301136389.html
SOURCE Biocept, Inc.